On May 21, Equities researchers at Telsey Advisory Group decreased their price target on shares of ROI Acquisition Corp (NASDAQ:EVRY) from $6.00 to $3.00 in a research report issued on Monday. The firm currently has a “not rated” rating on the stock. Telsey Advisory Group’s target price would suggest a potential upside of 194.12% from the company’s current price. ROI Acquisition Corp (NASDAQ:EVRY) net profit margin is -3.90% and weekly performance is 17.02%. On last trading day company shares ended up $1.10. Analysts mean target price for the company is $3.00. ROI Acquisition Corp (NASDAQ:EVRY) distance from 50-day simple moving average (SMA50) is -63.40%.
On May 14, 2014 Five9, Inc. (NASDAQ:FIVN) a leading provider of cloud contact center software, announced that members of its management team will present the investor conferences: The Bank of America Merrill Lynch 2014 Global Technology Conference in San Francisco at the Ritz Carton Hotel on Wednesday, June 4th at 10:00 AM Pacific Time. Five9 Inc (NASDAQ:FIVN) shares advanced 6.39% in last trading session and ended the day on $7.49. Gross Margin is 42.00% and its return on assets is -143.60%.
Viggle Inc. (Nasdaq:VGGL) announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”) for U.S. Patent Application No. 13/802,722, titled “Portfolio Optimization for Media Merchandising.” The patent allowance protects Viggle Inc.’s proprietary technology that analyzes content distribution patterns over time to recommend the most optimal time and channel for distributing content to achieve higher levels of engagement. The technology enables networks and brands that utilize the Viggle Platform to execute more effective marketing campaigns around their content. Viggle Inc (NASDAQ:VGGL) shares moved up 8.69% in last trading session and was closed at $5.63, while trading in range of $5.16 – $5.80. Viggle Inc (NASDAQ:VGGL) year to date (YTD) performance is -85.03%.
On May 15, 2014 Aastrom Biosciences, Inc. (NASDAQ:ASTM) the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, reported financial results for the quarter ended March 31, 2014. Aastrom reported a net loss for the quarter ended March 31, 2014 of $6.0 million, or $1.26 per share, compared to $5.5 million, or $3.00 per share, for the same period a year ago. The change in net loss from the prior year is due primarily to the non-cash change in the fair value of warrants and decreases in both research and development and selling, general and administrative expenses. Aastrom Biosciences Inc (NASDAQ:ASTM) ended the last trading day at $5.05. Company weekly volatility is calculated as 8.69% and price to cash ratio as 3.72. Aastrom Biosciences Inc (NASDAQ:ASTM) showed a positive weekly performance of 21.69%.
Sky-mobi Limited (ADR) (NASDAQ:MOBI) a leading mobile application platform in China, announced that the Company’s Board of Directors has approved a fiscal year-end change from March 31 to December 31, beginning in the calendar year ending December 31, 2014. Additionally, the Company also announced that its Board of Directors has approved a program to repurchase up to US$20 million of the Company’s American depositary shares (“ADSs”) over the next 12-month period, ending on May 30, 2015. Sky-mobi Ltd (ADR) (NASDAQ:MOBI) net profit margin is 5.30% and weekly performance is 3.69%. On last trading day company shares ended up $7.31. Analysts mean target price for the company is $7.50. Sky-mobi Ltd (ADR) (NASDAQ:MOBI) distance from 50-day simple moving average (SMA50) is -3.52%.